Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
Launched by MINGGE LLC · Dec 16, 2022
Trial Information
Current as of July 01, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving the way doctors diagnose gliomas, which are a type of brain tumor, during surgery. The goal is to use a combination of advanced imaging techniques, like magnetic resonance imaging (MRI) and ultrasound, along with artificial intelligence, to quickly identify important features of the tumor. This rapid diagnosis could help doctors create personalized plans for safely removing the tumor, making the surgery more effective and tailored to each patient.
To participate in this trial, individuals must be over 18 years old and have a glioma that can be surgically removed. They will go through standard imaging tests before surgery and will have their tumor analyzed after the operation. It’s important to note that participation is voluntary, and patients will read and agree to an informed consent document before joining the study. The trial is currently active but not recruiting new participants. Overall, the study aims to enhance the surgical treatment of gliomas by providing real-time information that helps guide doctors during surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age over 18 years old
- • Tumor in non-functional areas of the cerebral hemisphere.
- • Preoperative diagnosis of glioma.
- • Undergo glioma removal surgery.
- Exclusion Criteria:
- • Postoperative confirmation of non-glioma.
- • Magnetic resonance or ultrasound data not available.
About Mingge Llc
Mingge LLC is a dynamic clinical trial sponsor dedicated to advancing innovative therapeutic solutions through rigorous scientific research. With a focus on enhancing patient outcomes, the company specializes in designing and managing clinical trials across various therapeutic areas, leveraging cutting-edge methodologies and technology-driven approaches. Mingge LLC is committed to fostering collaborative partnerships with healthcare professionals, research institutions, and regulatory bodies, ensuring adherence to the highest standards of ethics and compliance. Through its comprehensive expertise and a patient-centered approach, Mingge LLC aims to contribute significantly to the development of safe and effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Zhifeng Shi, DM
Study Director
Huashan Hospital
Jinhua Yu, DE
Study Chair
Fudan University
Yinhui Deng, DE
Principal Investigator
Fudan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials